

# Competitive Pipeline Brief — Johnson & Johnson

Run date (UTC): 2026-01-08

Source URL	<a href="https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf">https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf</a>
Stored PDF	sources/jnj/2026-01-08.pdf
SHA256	7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04
Extracted 'as of' date	Unknown
Programs extracted	0

## Executive summary

### Johnson & Johnson Undergoes Significant Pipeline Streamlining and Advancement

Johnson & Johnson's latest pipeline update showcases a substantial restructuring, with over 80 assets and indications removed from the development roadmap. This extensive change predominantly reflects the successful advancement and commercialization of key assets, including new indications or formulations for established blockbusters such as CARVYKTI, DARZALEX, RYBREVANT, AKEEGA, and ERLEADA, particularly bolstering the oncology franchise. Additionally, several late-stage programs in immunology (e.g., nipocalimab, TREMFYA, STELARA) and neuroscience (e.g., CAPLYTA, SPRAVATO) appear to have transitioned from the development pipeline, likely due to regulatory approvals or completion of pivotal trials. Concurrently, a notable number of earlier-stage, wholly-owned 'JNJ-' numbered candidates across various therapeutic areas have also been removed, suggesting a strategic pruning to enhance R&D efficiency and reallocate resources towards programs with higher strategic conviction.

## Why it matters

- Reinforces J&J's strong execution in advancing late-stage assets through clinical development to regulatory approval and market, particularly in high-value therapeutic areas.
- Indicates potential for sustained revenue growth and market share expansion from recently approved indications and formulations, especially within the oncology and immunology segments.
- Suggests a more disciplined and focused R&D approach, potentially freeing up resources for higher-priority internal programs, external innovation, or strategic acquisitions.
- May create pipeline gaps in certain early-stage therapeutic areas, necessitating a clear strategy for replenishment through internal discovery or business development.
- Highlights the company's commitment to optimizing its portfolio, allowing for a concentrated effort on programs with the greatest potential for patient impact and commercial success.

## Watchlist

- Monitor commercial performance and market uptake of recently launched or expanded products, especially in multiple myeloma (CARVYKTI, TALVEY, TECVAYLI) and prostate cancer (AKEEGA, ERLEADA).
- Watch for official company announcements or investor presentations that provide further clarity on the rationale for specific early-stage asset removals.
- Assess future pipeline updates for new entries or strategic acquisitions that signal J&J's strategy to replenish and diversify its R&D portfolio.

- Analyze Q3/Q4 earnings call transcripts for executive commentary on updated R&D; strategy, pipeline priorities, and potential resource reallocation.
- Keep an eye on competitive landscape developments in therapeutic areas where J&J has pruned its early-stage pipeline, identifying potential emerging threats or opportunities.

## Pipeline snapshot (counts by phase)

No programs extracted in this run.

## Change log (previous vs current)

Confidence score (0–1): 0.55

New / Added items

None detected.

Removed / Discontinued items

Asset	Indication	Phase/Change
AKEEGA (niraparib/abiraterone)	M1 Metastatic Castration-Sensitive Prostate Cancer	
Bleximeneb	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine	
Bleximeneb	Relapsed Refractory Acute Myeloid Leukemia	
CABENUVA	HIV Adolescents	
CAPLYTA (lumateperone)	Adjunctive Treatment for Major Depressive Disorder	
CAPLYTA (lumateperone)	Bipolar Mania	
CAPLYTA (lumateperone)	Pediatric Psychiatric Indications	
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma TNI	
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma Transplant Eligible vs ASCT	
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible	
DARZALEX (daratumumab)	Smoldering Multiple Myeloma	
ERLEADA (apalutamide)	High Risk Prostate Cancer	
ERLEADA (apalutamide)	Localized Prostate Cancer	
icotrokinra	Psoriasis	
icotrokinra	Psoriatic Arthritis	
icotrokinra	Ulcerative Colitis	
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis	
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis Pediatrics	
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)	
IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma	
INLEXZO (gemcitabine intravesical injection)	High Risk Non Muscle Invasive Bladder Cancer BGC Experienced	

INLEXZO (gemcitabine intravesical <del>System</del> Muscle Invasive Bladder Cancer	
INLEXZO (gemcitabine intravesical <del>System</del> Muscle Invasive Bladder Cancer BCG-naïve High Risk	
ITI-1284	Alzheimer's Disease-Related Agitation
ITI-1284	Alzheimer's Disease-Related Psychosis
ITI-1284	Generalized Anxiety Disorder
JNJ-0387	Solid Tumors
JNJ-0631 (ARX305)	Renal Cancer
JNJ-0683 (ARX788)	Breast Cancer
JNJ-1493	Hematological Malignancies
JNJ-1887 sCD59	Geographic Atrophy
JNJ-1900 (NBTXR3)	Head and Neck Cancer
JNJ-1900 (NBTXR3)	Lung Cancer
JNJ-2056 (tau active immunotherapy)	Alzheimer's Disease
JNJ-2638	Gastrointestinal Cancer
JNJ-2761	Multiple Myeloma
JNJ-3413	Lymphoma
JNJ-4496	Hematological Malignancies
JNJ-4680	Lung Cancer
JNJ-4681	Hematological Malignancies
JNJ-4804 Co-antibody Therapy	Crohn's Disease
JNJ-4804 Co-antibody Therapy	Psoriatic Arthritis
JNJ-4804 Co-antibody Therapy	Ulcerative Colitis
JNJ-4916	Lung Cancer
JNJ-5108	Immunological Diseases
JNJ-5120	Major Depressive Disorder
JNJ-5322	Multiple Myeloma
JNJ-5939	Atopic Dermatitis
JNJ-6420	Prostate Cancer
JNJ-6848	Immunological Diseases
JNJ-7446	Lung Cancer
JNJ-7528	Atopic Dermatitis
JNJ-8177 (ARX517)	Prostate Cancer
JNJ-8377	Lymphoma
JNJ-8543	Hematological Malignancies
JNJ-9401	Prostate Cancer
JNJ-9530	Hematological Malignancies
JNJ-9892	Hematological Malignancies

JNJ-9968	Hematological Malignancies
macitentan	Pulmonary Arterial Hypertension 75mg
milvexian (Factor Xla)	Acute Coronary Syndrome
milvexian (Factor Xla)	Atrial Fibrillation
milvexian (Factor Xla)	Secondary Stroke Prevention
nipocalimab	Chronic Inflammatory Demyelinating Polyneuropathy
nipocalimab	Fetal and Neonatal Alloimmune Thrombocytopenia
nipocalimab	Hemolytic Disease of the Fetus and Newborn
nipocalimab	Idiopathic Inflammatory Myopathy
nipocalimab	Sjogren's Disease
nipocalimab	Systemic Lupus Erythematosus
nipocalimab	Warm Autoimmune Hemolytic Anemia
pasritamig	Prostate Cancer
posdinemab	Alzheimer's Disease
RPGR Gene Therapy	Retinitis Pigmentosa
RYBREVANT (amivantamab)	
RYBREVANT (amivantamab)	Colorectal Cancer
RYBREVANT (amivantamab)	Colorectal Cancer 2L
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy
seltorexant	Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms
SIMPONI (golimumab)	Pediatric Ulcerative Colitis
SIRTURO	Leprosy
SIRTURO	Tuberculosis Long Acting
SPRAVATO (esketamine)	Major Depressive Disorder with Suicidal Ideation Pediatrics
SPRAVATO (esketamine)	Treatment Resistant Depression monotherapy
STELARA (ustekinumab)	Pediatric Crohn's Disease
STELARA (ustekinumab)	Pediatric Ulcerative Colitis
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma A-CD38 Naïve
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma CD38 exposed
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed
TALVEY + TECVAYLI	TIE NDMM in combination with DR
TAR-210 (RIS/erdafitinib)	Intravesical Delivery System for Localized Bladder Cancer
TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs
TECVAYLI (teclistamab)	Relapsed Refractory Multiple Myeloma CD38 exposed
TECVAYLI (teclistamab)	TE NDMM maintenance
TECVAYLI (teclistamab)	TIE NDMM in combination with DR

TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis
TREMFYA (guselkumab)	Pediatric Psoriasis
TREMFYA (guselkumab)	Pediatric Ulcerative Colitis
TREMFYA (guselkumab)	Psoriatic Arthritis Structural Damage
TREMFYA (guselkumab)	Ulcerative Colitis Subcutaneous Induction
UPTRAVI (selexipag)	Pediatric Pulmonary Arterial Hypertension

Phase changes

None detected.